EISAI CO. LTD/ JP3160400002 /
2024-04-19 8:26:01 AM | Chg. +0.4500 | Volume | Bid9:25:57 PM | Ask9:25:57 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
35.4900EUR | +1.28% | 0 Turnover: 0.0000 |
-Bid Size: - | -Ask Size: - | 10.32 bill.EUR | - | - |
GlobeNewswire
03-29
Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
GlobeNewswire
03-27
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regula...
GlobeNewswire
03-12
How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Fai...
GlobeNewswire
03-04
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire
02-28
PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invas...
GlobeNewswire
02-22
Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, A...
GlobeNewswire
01-22
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., ...
GlobeNewswire
2023-12-19
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European C...
GlobeNewswire
2023-12-07
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commerci...
GlobeNewswire
2023-12-05
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian C...
GlobeNewswire
2023-11-17
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparl...
GlobeNewswire
2023-11-06
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develo...
GlobeNewswire
2023-11-02
Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleot...
GlobeNewswire
2023-10-30
Abingworth raises $356 million for new Clinical Co-Development Co-Investment Fund (CCD-CIF)
GlobeNewswire
2023-10-25
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study ...
GlobeNewswire
2023-10-23
Elevar Therapeutics Names Brian Cunningham Vice President of Sales and Kenneth Rankin Vice President...
GlobeNewswire
2023-10-23
SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors
GlobeNewswire
2023-10-19
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
GlobeNewswire
2023-10-18
X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors
GlobeNewswire
2023-09-26
Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab ...
GlobeNewswire
2023-09-25
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan